HBV Therapies (Industry News)

SciClone Initiates Study of Zadaxin Plus Lamivudine for Hepatitis B

Published in Hepatitis Weekly, February 7th, 2000

SciClone Pharmaceuticals announced the start of a US Phase II hepatitis B study using Zadaxin, the company's host immune system enhancer (h-ISE), in combination with lamivudine, a US Food and Drug Administration (FDA)-approved nucleoside analogue.

The study, conducted at Loyola University of Chicago, Illinois, will assess the safety and efficacy of the combination in the treatment of chronic hepatitis B patients.

Approximately 1.2 million people in the USare chronic carriers of hepatitis B. Lamivudine currently is used as a single-agent treatment. However, treatment with nucleoside analogues alone can result in drug-resistant mutations of the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry